David V. Gauvin, et al. “Defining ‘Best Practices’ for Critical Endpoints in Preclinical Screening of New Chemical Entities for Ototoxicity Liability”. Otolaryngology, vol. 2, no. 2, May 2016, pp. 58-69, https://openventio.us/index.php/OOJ/article/view/2437.